Concepedia

Carter DuFrane

CD

Statistics

Publications

7

Citations

362

H-Index

7

Active since

2019

Affiliations

Alliance Foundation Trials(Current)

Dana-Farber Cancer Institute

Breast International Group

Institut Jules Bordet

Harvard University

Carter DuFrane is an author at Alliance Foundation Trials specializing in oncology, pharmacology, and medicine.

Publications per year

2019–2026

7

Publications

7

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín et al. · The Lancet Oncology · 2021 · 255 citations

, , +15

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

Helen J. Ross, David Kozono, James J. Urbanic et al. · Journal of Clinical Oncology · 2021 · 36 citations

, , +17

ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

Shigehira Saji, Heather L. McArthur, Michail Ignatiadis et al. · Journal of Clinical Oncology · 2021 · 16 citations · Full text

, , +17

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

Otto Metzger, Sumithra Mandrekar, S. Goel et al. · New England Journal of Medicine · 2026 · 15 citations

, , +17

AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).

Helen J. Ross, David Kozono, James J. Urbanic et al. · Journal of Clinical Oncology · 2020 · 14 citations

, , +17

1–5 of 7